Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $54M (up 325.8% year over year) with net income of $3M.
Q3 2026 key financials · XBRL
- Revenue
- $54M
- +325.8% YoY · +506.2% QoQ
- Net income
- $3M
- +111.3% YoY · +107.1% QoQ
- Operating margin
- -3.6%
Source: XBRL data from the Monte Rosa Therapeutics, Inc. (GLUE) Q3 2026 10-Q on SEC EDGAR. USD.
Monte Rosa Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly collaboration revenue $54.4M, up $41.6M YoY from $12.8M
- Net income $3.1M vs $27.1M loss YoY, operating margin (3.6%) vs (72.1%)
- MRT-8102 largest R&D line at $5.6M, MRT-6160 lowest at $1.4M
- Cash, equivalents, restricted cash and securities $582.6M; operating cash flow $(122.5)M
- $323.8M net proceeds from 2026 offering; cash runway expected into 2029
Risk Factors
- Continued operating losses, net loss $84.8 million for nine months ended September 30, 2026
- Cash, equivalents, restricted cash and marketable securities $582.6 million as of September 30, 2026
- Development spending risk: Phase 2 trials for MRT-2359 and MRT-8102 increasing expenses
- Profitability risk: accumulated deficit reached $562.1 million as of September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monte Rosa Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.